Medications to Manage Injection Site Reactions on Mounjaro (tirzepatide for T2D): First-Line and Beyond

What the Mounjaro label says about the injection

Mounjaro is a once-weekly subcutaneous injection, a glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist approved to improve blood sugar in adults and children 10 years of age and older with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk for these events [1].

The label's practical instructions are about technique. It says injections can be given in the abdomen or thigh, or in the back of the upper arm by another person, and says to rotate sites with each dose [1]. It is given once weekly, at any time of day, with or without meals [1].

Who tends to get these reactions

In the label's pool of placebo-controlled adult trials, injection site reactions were reported in 3.2% of Mounjaro-treated patients versus 0.4% of placebo-treated patients [1].

In a combined immunogenicity analysis of seven phase 3 trials in 5,025 people with type 2 diabetes, treatment-emergent anti-tirzepatide antibodies developed in 51.1% of treated patients. Antibody-positive patients had more hypersensitivity reactions and injection site reactions than antibody-negative patients, and most of those events were nonserious and nonsevere; most occurred or resolved regardless of antibody status or antibody titer [2]. The label gives 119 of 2,570 antibody-positive adults (4.6%) versus 18 of 2,455 antibody-negative adults (0.7%) for injection site reactions [1].

A 2026 review included 24 phase 3 trials, 23 of which were eligible for its network meta-analysis. It found that tirzepatide was associated with a higher risk of injection site reactions [3]. That analysis covered adults treated at weight-management doses [3], a different group from the adults with type 2 diabetes in Mounjaro's trials [1].

What the label says to do about a serious reaction

Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with Mounjaro [1]. The label directs that if a hypersensitivity reaction occurs, Mounjaro should be discontinued, the reaction treated promptly per standard of care, and the patient monitored until signs and symptoms resolve [1].

Mounjaro is contraindicated in people with a known serious hypersensitivity to tirzepatide or any of its excipients [1]. The label also advises caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist, since it is unknown whether those patients are predisposed to the same reactions with Mounjaro [1].

Oral medicines and the stomach-emptying caution

Mounjaro delays gastric emptying, and the label says this has the potential to affect the absorption of oral medicines taken at the same time. It advises caution when oral medicines are used together with Mounjaro, and monitoring of drugs that depend on threshold concentrations for efficacy or have a narrow therapeutic index, such as warfarin [1]. That caution is written for oral medicines in general [1].